bitunix
DaVita Inc.
DaVita Inc.
DaVita Inc.
DVA
DVA
NYSE
Health Services
Medical/Nursing Services
192.57
USD
+8.64
+4.70%
Open: 10-29 16:11 (UTC+0)

DVA Key Statistics

High
194.30
Open
190.01
Volume
635.50K
Low
184.27
Prev. Close
183.93
Trading Value
120.65M
52-Week High
247.49
Relative Volume
1.408
Amplitude (%)
5.45%
52-Week Low
101.00
Turnover Rate
1.00%
Market Cap
12.28B
P/E Ratio (TTM)
15.51
P/E Ratio (Annual)
18.283
P/B Ratio
-15.34
P/S Ratio
0.86
Earnings Per Share (EPS)
11.857
Dividend (TTM)
0
Dividend Yield
0.00%
Shares Outstanding
63.80M
Currency Unit
USD

DVA Price Performance

7 day
30 day
90 day
180 day
Year to date
1 Year
DVA Money Flow Distribution
DVA Daily Short Sale Volume
DVA Short Interest History
As of 2026-10-29, the DaVita Inc. (DVA) stock price today is 192.57. Based on this price, the company has a market capitalization of $12.28B, with a P/E ratio of 15.51. On 2026-10-29, DVA traded between 184.27 and 194.30. Today’s stock price is 4.50% above the daily low and 0.89% below the daily high, placing DVA near the upper end of its most recent trading range. Trading volume currently stands at 635.50K, compared with an average daily volume of 451.52K. This suggests that trading activity is above its usual level than usual. Over the past year, DaVita Inc. shares have traded between 101.00 and 247.49. At today’s price, DVA is 90.66% above its 52-week low and 22.19% below its 52-week high.
Company Name
DaVita Inc.
Sector
Health Services
Industry
Medical/Nursing Services
Exchanges
NYSE
Number of Employees
78,000
Lot Size
100
Official Website
Currency Unit
USD
DaVita Inc. (DVA) is a kidney-care services company that provides kidney dialysis services through a large network of outpatient centers and home-treatment programs. It treats patients with chronic kidney disease and end-stage renal disease, with revenue reimbursed by Medicare, other government programs and commercial insurers. It operates more than 3,200 facilities worldwide and treats about 300,000 patients annually, with roughly 35% of the U.S. dialysis market. About two-thirds of U.S. revenue is reimbursed at government rates, while commercially insured patients represent a smaller share of patients but most U.S. dialysis profits. The company ranks among the largest organizations in its primary market.

DVA FAQ